← Eichor
Study identifier: NCT07714668 Synced from ClinicalTrials.gov · July 28, 2026
● Not Yet Recruiting

A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer

Condition: Ovarian Cancer · Recurrent Ovarian Cancer  ·  Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.

PhasePhase 2
Planned participants171
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is an open-label, multicenter Phase II clinical study conducted in subjects with recurrent ovarian cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trials Information Group officer  ·  031169085587  ·  ctr-contact@cspc.cn

Xiaohua Wu  ·  +86 21-13601772486  ·  wu.xh@fudan.edu.cn

Always discuss trial participation with your own doctor first.

Locations (0)

Locations not yet listed on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07714668